Search company, investor...
Ginkgo Bioworks company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Market Cap


Stock Price


About Ginkgo Bioworks

Ginkgo Bioworks (NYSE: DNA) designs and prints DNA. The company can design the living code to build custom microorganisms with lower environmental impact and waste for customers in a wide range of industries including pharmaceuticals, consumer goods, consumer electronics, cosmetics, nutrition, food, agriculture, medicine, and more. The company was founded in 2009 and is based in Boston, Massachusetts.

Ginkgo Bioworks Headquarters Location

27 Drydock Avenue 8th Floor

Boston, Massachusetts, 02210,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Ginkgo Bioworks

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Ginkgo Bioworks in 12 CB Insights research briefs, most recently on Jul 6, 2022.

Expert Collections containing Ginkgo Bioworks

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ginkgo Bioworks is included in 5 Expert Collections, including Synthetic Biology.


Synthetic Biology

687 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.



3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.


Food & Beverage

128 items

Ginkgo Bioworks Patents

Ginkgo Bioworks has filed 30 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • Transcription factors
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Transcription factors, Gene expression, Genetics, Human proteins


Application Date


Grant Date



Related Topics

Molecular biology, Transcription factors, Gene expression, Genetics, Human proteins



Latest Ginkgo Bioworks News

President Biden wants to build a 'bioeconomy.' Here's what that means for Boston.

Sep 20, 2022

"My view is that out-there stuff is Boston's strength," said Ginkgo Bioworks' Jason Kelly, who attended the White House's bioeconomy summit last week. "I think we should drive a truck through this. I think this is going to be a great opportunity for Boston."

Ginkgo Bioworks Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ginkgo Bioworks Rank

  • When was Ginkgo Bioworks founded?

    Ginkgo Bioworks was founded in 2009.

  • Where is Ginkgo Bioworks's headquarters?

    Ginkgo Bioworks's headquarters is located at 27 Drydock Avenue, Boston.

  • What is Ginkgo Bioworks's latest funding round?

    Ginkgo Bioworks's latest funding round is PIPE.

  • How much did Ginkgo Bioworks raise?

    Ginkgo Bioworks raised a total of $796.25M.

  • Who are the investors of Ginkgo Bioworks?

    Investors of Ginkgo Bioworks include Baillie Gifford & Co., Soaring Eagle Acquisition, National Institutes of Health, Viking Global Investors, General Atlantic and 21 more.

  • Who are Ginkgo Bioworks's competitors?

    Competitors of Ginkgo Bioworks include Biosyntia and 5 more.

You May Also Like


Epic specializes in the development of software for healthcare organizations.

Verily Life Sciences Logo
Verily Life Sciences

Verily Life Sciences develops tools and devices to collect, organize and activate health data, and creates interventions to prevent and manage the disease. It partners with leading life sciences, medical devices, and government organizations, using deep hardware, software, scientific, and healthcare expertise to enable faster development, meaningful advances, and deployment at scale. The company was founded in 2015 and is based in South San Francisco, California.

Helix Logo

Helix connects people with the most fundamental aspect of what makes them unique: their own DNA. The company empowers consumers to discover and explore their own genomes through insights provided by its ecosystem of content partners.

Cureety Logo

Cureety develops remote monitoring software for healthcare establishments. Its digital solution improves patients' care pathway, makes life easier for healthcare teams, and collects new data for researchers.


Intellhealth offers an intelligent data management software that accelerates the diagnosis and prescriptive process for patients and providers.

AdhereTech Logo

Digital Medical Technologies, dba AdhereTech, creates bottles that measure pills or liquid in real-time, wirelessly send this HIPAA-compliant data into the cloud, and remind patients to take their medication via automated phone call or text message.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.